

Performance Against Time to Target

REC Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
15/SC/0397	183591	An evaluation of the tolerance and acceptability of Neocate Junior, an amino acid based feed for children.	Number Agreed	3	3	Date Agreed	31/07/2016	2	31/07/2016	2	Recruitment Finished
15/LO/0900	167412	RESP 4480 (Emphysema)	Number Agreed	4	4	Date Agreed	31/10/2016	2	30/09/2016	2	Recruitment Finished
13/YH/0201	129722	Sativex Severe Spasticity	Number Agreed	6	6	Date Agreed	31/12/2015	5	01/07/2016	5	Recruitment Finished
13/LO/0161	114841	CCRN 2104 (Eisenmenger Syndrome)	Number Agreed	3	3	Date Agreed	01/10/2016	1	20/07/2016	1	Recruitment Finished
15/NW/0631	185354	CHIL4901 (OKAH-193)	Number Agreed	100	100	Date Agreed	31/07/2016	100	27/07/2016	100	Recruitment Finished
14/SC/1425	159287	GX29185	Number Agreed	7	7	Date Agreed	31/10/2016	7	28/07/2016	7	Recruitment Finished
15/YH/0407	183603	CANC - 4814	Number Agreed	4	4	Date Agreed	08/08/2016	0	03/08/2016	0	Withdrawn By Sponsor
15/LO/0517	170613	CANC - 4281 - YOSEMITE	Number Agreed	5	5	Date Agreed	30/08/2016	1	08/08/2016	1	Recruitment Finished
13/NW/0321	130144	MCRN234 (WA28118)	Number Agreed	2	2	Date Agreed	30/10/2016	2	10/08/2016	2	Recruitment Finished
15/EE/0405	189187	DIAB 4501	Number Agreed	4	4	Date Agreed	01/07/2016	4	15/08/2016	4	Recruitment Finished
15/LO/0413	171579	Safety and Efficacy of Brimonidine-DDS in patients with GA-AMD	Number Agreed	3	3	Date Agreed	31/08/2016	3	09/09/2016	3	Recruitment Finished
13/SC/0007	118729	An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients with Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Unresectable Melanoma.	Number Agreed	5	5	Date Agreed	01/08/2016	4	28/09/2016	4	Recruitment Finished
16/HRA/0128	198232	NEUTROPENIC SEPSIS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER	Number Agreed	18	18	Date Agreed	30/06/2016	18	31/07/2016	22	Recruitment Finished
14/YH/1037	149080	MCRN3102 (KF5503/65)	Number Agreed	4	4	Date Agreed	28/11/2016	1	13/10/2016	1	Withdrawn By Sponsor
12/SW/0084	96688	LFG316 (CLFG316A2204)	Number Agreed	5	5	Date Agreed	30/11/2016	6	22/11/2016	6	Recruitment Finished
14/LO/1617	159770	GLP110933 study Type I DM Study (DRN 3266)	Number Agreed	2	2	Date Agreed	18/11/2016	2	30/11/2016	3	Recruitment Finished
15/WA/0360	184197	The TARGET All Comer Clinical Trial	Number Agreed	80	80	Date Agreed	16/12/2016	124	17/10/2016	124	Recruitment Finished
13/NW/0002	114402	CCRN 1073 (Thoracic aortic surgery)	Number Agreed	15	15	Date Agreed	30/11/2016	21	30/11/2016	21	Recruitment Finished
13/EM/0012	114274	NCRN490: CA184-178 Ipilimumab in children(aged 12<18)with malignant melanoma	Number Agreed	1	1	Date Agreed	30/06/2016	0	28/07/2016	0	Recruitment Finished
15/EE/0464	183877	CRIT 4440	Number Agreed	3	3	Date Agreed	30/11/2016	2	30/11/2016	2	Recruitment Finished
15/SC/0603	114842	CCRN 2393 MAESTRO-OL	Number Agreed	1	1	Date Agreed	01/04/2017	1	01/12/2016	1	Recruitment Finished
15/WS/0121	173661	CANC - 4556	Number Agreed	4	4	Date Agreed	31/12/2016	4	09/12/2016	4	Recruitment Finished
15/SC/0311	181166	CARD 4677 VEST III PMS	Number Agreed	15	15	Date Agreed	31/01/2017	15	31/01/2017	15	Recruitment Finished
12/NW/0367	104793	PLUTO	Number Agreed	0	0	Date Agreed	31/01/2017	0	01/02/2017	0	Recruitment Finished
16/NW/0262	200188	RESP 5664	Number Agreed	1	1	Date Agreed	10/03/2017	3	10/03/2017	3	Recruitment Finished
15/SC/0242	173490	HAEM 4448	Number Agreed	1	1	Date Agreed	30/03/2021	0	13/03/2017	0	Recruitment Finished
16/LO/0055	179500	OPHT 4645	Number Agreed	8	8	Date Agreed	24/03/2017	8	30/03/2017	8	Recruitment Finished
15/SC/0409	183061	OPHT 4170 (AMD)	Number Agreed	8	8	Date Agreed	01/06/2017	8	07/04/2017	8	Recruitment Finished
13/LO/1081	132715	PROSPER: MDV3100-14	Number Agreed	6	6	Date Agreed	30/06/2017	9	23/03/2017	9	Recruitment Finished

Performance Against Time to Target

REC Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
15/LO/2045	193136	CHIL 5229 SMT C1100 in Ambulatory Boys with DMD	Number Agreed	2	2	Date Agreed	10/02/2017	2	10/02/2017	2	Recruitment Finished
16/SC/0161	186322	GO29438 PhaseIII?Study-Atezolizumab?with?chemotherapy?in?Stage?IV?Non-Squamous	Number Agreed	4	4	Date Agreed	31/07/2017	5	07/04/2017	5	Recruitment Finished
15/LO/1236	183416	NEOD001 versus placebo in AL Amyloidosis	Number Agreed	1	1	Date Agreed	31/05/2017	0	21/04/2017	0	Recruitment Finished
16/SC/0018	191267	Study of CTX 4430 in Cystic Fibrosis Patients	Number Agreed	2	2	Date Agreed	15/05/2017	3	16/05/2017	3	Recruitment Finished
15/ES/0001	193859	GED-0301-CD-002 PhIII study for subjects with Active Crohn?s Disease (REVOLVE)	Number Agreed	3	3	Date Agreed	31/08/2017	1	22/05/2017	1	Withdrawn By Host
16/LO/1612	201997	Follow-up Study for Patients who Completed Study ALX0681-C301	Number Agreed	1	1	Date Agreed	30/11/2017	1	08/06/2017	1	Recruitment Finished
15/EM/0437	184390	COLUMBUS-AMD	Number Agreed	3	3	Date Agreed	30/06/2017	3	09/06/2017	3	Recruitment Finished
14/YH/1263	162807	CRIT 3719 (Intravascular glucose monitoring system)	Number Agreed	5	5	Date Agreed	30/06/2016	3	05/04/2017	3	Withdrawn By Sponsor